1173023-51-2

Bufuralol-d₉ is intended for use as an internal standard for the quantification of bufuralol by GC- or LC-MS. Bufuralol is a non-selective antagonist of β-adrenergic receptors (β-ARs) that also has partial agonist activity. It decreases mean arterial blood pressure and increases abdominal aortic blood flow in anesthetized cats when administered intravenously at doses of 0.3 and 1 mg/kg. Bufuralol is hydroxylated at the 1'' position by the cytochrome P450 (CYP) isoform CYP2D6 and has been used as a substrate to measure CYP2D6 activity.

A b-Adrenergic blocker with peripheral vasodilating activity. Antianginal

[1] SHIZUO NARIMATSU. Stereoselectivity in the oxidation of bufuralol, a chiral substrate, by human cytochrome P450s[J]. Chirality, 2003, 15 4: 333-339. DOI: 10.1002/chir.10212
[2] TH PRINGLE. Pharmacodynamic and pharmacokinetic studies on bufuralol in man.[J]. British journal of clinical pharmacology, 1986, 22 5: 527-534. DOI: 10.1111/j.1365-2125.1986.tb02931.x
[3] L. BLABER. The effects of bufuralol, a beta-adrenoceptor antagonist with predominant beta 2-adrenoceptor agonistic activity, in the cat and the dog.[J]. Journal of Cardiovascular Pharmacology, 1984, 6 1 1: 165-175. DOI: 10.1097/00005344-198401000-00025
[4] MARK J.I. PAINE . Functional High Level Expression of Cytochrome P450 CYP2D6 Using Baculoviral Expression Systems[J]. Archives of biochemistry and biophysics, 1996, 328 1: Pages 143-150. DOI: 10.1006/abbi.1996.0154
[5] NANCY CHEN. In vitro drug-drug interactions of budesonide: inhibition and induction of transporters and cytochrome P450 enzymes.[J]. Xenobiotica, 2018, 48 6: 637-646. DOI: 10.1080/00498254.2017.1344911